ALLMedicine™ Myelodysplastic Syndromes Center
Research & Reviews 6,231 results
https://doi.org/10.3324/haematol.2020.272559
Haematologica Jachiet V, Moulis G et. al.
Feb 25th, 2021 - Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are associated with systemic inflammatory or autoimmune diseases in 10-20 % of cases. Among them, immune thrombocytopenia (ITP) has been reported but large studies assessin...
https://doi.org/10.1080/16078454.2021.1889161
Hematology (Amsterdam, Netherlands); Cheng WY, Satija A et. al.
Feb 25th, 2021 - To evaluate hypomethylating agent (HMA) persistence in patients with myelodysplastic syndromes (MDS), and examine its association with healthcare resource utilization (HRU) and progression to acute myeloid leukemia (AML). A total of 2,400 adults d...
https://doi.org/10.1111/trf.16093
Transfusion Bowen D, Karakantza M
Feb 22nd, 2021 - Thrombocytopenia and platelet transfusion in myelodysplastic syndromes.|2021|Bowen D,Karakantza M,|
https://doi.org/10.1002/cam4.3786
Cancer Medicine; Yan X, Wang L et. al.
Feb 20th, 2021 - To explore the relevance of cytogenetic or molecular genetic abnormalities to clinical variables, including clinical and laboratory characteristics and prognosis in Chinese patients with myelodysplastic syndromes (MDS). A total of 634 consecutive ...
https://doi.org/10.1200/JCO.20.02342
Journal of Clinical Oncology : Official Journal of the Am... Cluzeau T, Sebert M et. al.
Feb 18th, 2021 - TP53-mutated (TP53m) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have very poor outcome irrespective of the treatment received, including 40% responses (20% complete remission [CR]) with azacitidine (AZA) alone, short response...
Guidelines 31 results
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Soc... Fenaux P, Haase D et. al.
Nov 22nd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|diagnosis,epidemiology,therapy,
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/
May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).
http://www.hematology.org/Clinicians/Guidelines-Quality/503.aspx
Allen, S.
Feb 20th, 2018 - These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.
https://doi.org/10.6004/jnccn.2017.0007
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Stone RM et. al.
Jan 3rd, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...
http://www.bloodjournal.org/content/122/17/2943
Malcovati, L.,et al.
Oct 23rd, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit.
Drugs 57 results see all →
Clinicaltrials.gov 6,485 results
https://doi.org/10.3324/haematol.2020.272559
Haematologica Jachiet V, Moulis G et. al.
Feb 25th, 2021 - Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are associated with systemic inflammatory or autoimmune diseases in 10-20 % of cases. Among them, immune thrombocytopenia (ITP) has been reported but large studies assessin...
https://doi.org/10.1080/16078454.2021.1889161
Hematology (Amsterdam, Netherlands); Cheng WY, Satija A et. al.
Feb 25th, 2021 - To evaluate hypomethylating agent (HMA) persistence in patients with myelodysplastic syndromes (MDS), and examine its association with healthcare resource utilization (HRU) and progression to acute myeloid leukemia (AML). A total of 2,400 adults d...
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/transplant-may-improve-survival-in-older-patients-with-high-risk-myelodysplastic-syndrome/
Feb 24th, 2021 - Stem cell transplants are not frequently offered to older patients with high-risk myelodysplastic syndromes (MDS). According to a study from the Blood and Marrow Transplant Clinical Trials Network (BMTCTN 1102), these patients may indeed achieve a...
https://doi.org/10.1111/trf.16093
Transfusion Bowen D, Karakantza M
Feb 22nd, 2021 - Thrombocytopenia and platelet transfusion in myelodysplastic syndromes.|2021|Bowen D,Karakantza M,|
https://doi.org/10.1002/cam4.3786
Cancer Medicine; Yan X, Wang L et. al.
Feb 20th, 2021 - To explore the relevance of cytogenetic or molecular genetic abnormalities to clinical variables, including clinical and laboratory characteristics and prognosis in Chinese patients with myelodysplastic syndromes (MDS). A total of 634 consecutive ...
News 287 results
https://reference.medscape.com/viewarticle/944879
Feb 2nd, 2021 - Guidelines on the diagnosis and treatment of myelodysplastic syndromes were published in November 2020 by the European Society of Medical Oncology.[1] The diagnosis of myelodysplastic syndromes (MDS) is based on the blood count, the marrow aspirat...
https://www.medscape.com/viewarticle/933602
Jul 7th, 2020 - The Food and Drug Administration has approved Inqovi (decitabine and cedazuridine tablets, Astex Pharmaceuticals) to treat adults with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The agency's action gives physicians ...
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/
May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).
https://www.medscape.com/viewarticle/928198
Apr 5th, 2020 - The US Food and Drug Administration (FDA) has approved luspatercept (Reblozyl, Bristol-Myers Squibb/Acceleron) for the treatment of anemia in patients with myelodysplastic syndromes (MDS). The green light represents the first treatment advancement...
https://www.medscape.com/viewarticle/923569
Jan 9th, 2020 - (Reuters Health) - Therapy every 3 weeks with the drug luspatercept dramatically reduced the need for blood transfusions in a subset of patients with lower-risk myelodysplastic syndromes (MDS), according to results from the MEDALIST study reported...